Literature DB >> 25363063

Inhibition of L-carnitine biosynthesis and transport by methyl-γ-butyrobetaine decreases fatty acid oxidation and protects against myocardial infarction.

E Liepinsh1, M Makrecka-Kuka, J Kuka, R Vilskersts, E Makarova, H Cirule, E Loza, D Lola, S Grinberga, O Pugovics, I Kalvins, M Dambrova.   

Abstract

BACKGROUND AND
PURPOSE: The important pathological consequences of ischaemic heart disease arise from the detrimental effects of the accumulation of long-chain acylcarnitines in the case of acute ischaemia-reperfusion. The aim of this study is to test whether decreasing the L-carnitine content represents an effective strategy to decrease accumulation of long-chain acylcarnitines and to reduce fatty acid oxidation in order to protect the heart against acute ischaemia-reperfusion injury. KEY
RESULTS: In this study, we used a novel compound, 4-[ethyl(dimethyl)ammonio]butanoate (Methyl-GBB), which inhibits γ-butyrobetaine dioxygenase (IC₅₀ 3 μM) and organic cation transporter 2 (OCTN2, IC₅₀ 3 μM), and, in turn, decreases levels of L-carnitine and acylcarnitines in heart tissue. Methyl-GBB reduced both mitochondrial and peroxisomal palmitate oxidation rates by 44 and 53% respectively. In isolated hearts treated with Methyl-GBB, uptake and oxidation rates of labelled palmitate were decreased by 40%, while glucose oxidation was increased twofold. Methyl-GBB (5 or 20 mg·kg(-1)) decreased the infarct size by 45-48%. In vivo pretreatment with Methyl-GBB (20 mg·kg(-1)) attenuated the infarct size by 45% and improved 24 h survival of rats by 20-30%. CONCLUSIONS AND IMPLICATIONS: Reduction of L-carnitine and long-chain acylcarnitine content by the inhibition of OCTN2 represents an effective strategy to protect the heart against ischaemia-reperfusion-induced damage. Methyl-GBB treatment exerted cardioprotective effects and increased survival by limiting long-chain fatty acid oxidation and facilitating glucose metabolism.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25363063      PMCID: PMC4337704          DOI: 10.1111/bph.13004

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

2.  The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

Authors:  P F Kantor; A Lucien; R Kozak; G D Lopaschuk
Journal:  Circ Res       Date:  2000-03-17       Impact factor: 17.367

Review 3.  Mildronate: cardioprotective action through carnitine-lowering effect.

Authors:  Maija Dambrova; Edgars Liepinsh; Ivars Kalvinsh
Journal:  Trends Cardiovasc Med       Date:  2002-08       Impact factor: 6.677

4.  Activated peroxisomal fatty acid metabolism improves cardiac recovery in ischemia-reperfusion.

Authors:  Edgars Liepinsh; Elina Skapare; Janis Kuka; Marina Makrecka; Helena Cirule; Edijs Vavers; Eduards Sevostjanovs; Solveiga Grinberga; Osvalds Pugovics; Maija Dambrova
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-03-26       Impact factor: 3.000

5.  Targeting carnitine biosynthesis: discovery of new inhibitors against γ-butyrobetaine hydroxylase.

Authors:  Kaspars Tars; Janis Leitans; Andris Kazaks; Diana Zelencova; Edgars Liepinsh; Janis Kuka; Marina Makrecka; Daina Lola; Viktors Andrianovs; Daina Gustina; Solveiga Grinberga; Edvards Liepinsh; Ivars Kalvinsh; Maija Dambrova; Einars Loza; Osvalds Pugovics
Journal:  J Med Chem       Date:  2014-03-14       Impact factor: 7.446

6.  Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.

Authors:  Jason R B Dyck; Jie-Fei Cheng; William C Stanley; Rick Barr; Margaret P Chandler; Steven Brown; David Wallace; Thomas Arrhenius; Charles Harmon; Guang Yang; Alex M Nadzan; Gary D Lopaschuk
Journal:  Circ Res       Date:  2004-04-22       Impact factor: 17.367

7.  Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor, Etomoxir.

Authors:  G D Lopaschuk; G F McNeil; J J McVeigh
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

8.  Evolving myocardial infarction in the rat in vivo: an inappropriate model for the investigation of drug-induced infarct size limitation during sustained regional ischaemia.

Authors:  D J Hearse; V Richard; D M Yellon; J G Kingma
Journal:  J Cardiovasc Pharmacol       Date:  1988-06       Impact factor: 3.105

9.  Selective inhibition of OCTN2 is more effective than inhibition of gamma-butyrobetaine dioxygenase to decrease the availability of l-carnitine and to reduce myocardial infarct size.

Authors:  Edgars Liepinsh; Marina Makrecka; Janis Kuka; Helena Cirule; Elina Makarova; Eduards Sevostjanovs; Solveiga Grinberga; Reinis Vilskersts; Daina Lola; Einars Loza; Ilmars Stonans; Osvalds Pugovics; Maija Dambrova
Journal:  Pharmacol Res       Date:  2014-05-14       Impact factor: 7.658

10.  Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat.

Authors:  Pascal Degrace; Laurent Demizieux; Joseph Gresti; Marcelline Tsoko; Agnès André; Luc Demaison; Pierre Clouet
Journal:  Mol Cell Biochem       Date:  2004-03       Impact factor: 3.396

View more
  7 in total

1.  Mildronate triggers growth suppression and lipid accumulation in largemouth bass (Micropterus salmoides) through disturbing lipid metabolism.

Authors:  Jun-Xian Wang; Samad Rahimnejad; Yan-Yu Zhang; Jiong Ren; Jie Wang; Fang Qiao; Mei-Ling Zhang; Zhen-Yu Du
Journal:  Fish Physiol Biochem       Date:  2022-01-16       Impact factor: 2.794

Review 2.  Recent examples of α-ketoglutarate-dependent mononuclear non-haem iron enzymes in natural product biosyntheses.

Authors:  Shu-Shan Gao; Nathchar Naowarojna; Ronghai Cheng; Xueting Liu; Pinghua Liu
Journal:  Nat Prod Rep       Date:  2018-08-15       Impact factor: 13.423

Review 3.  Cardiac metabolism as a driver and therapeutic target of myocardial infarction.

Authors:  Coert J Zuurbier; Luc Bertrand; Christoph R Beauloye; Ioanna Andreadou; Marisol Ruiz-Meana; Nichlas R Jespersen; Duvaraka Kula-Alwar; Hiran A Prag; Hans Eric Botker; Maija Dambrova; Christophe Montessuit; Tuuli Kaambre; Edgars Liepinsh; Paul S Brookes; Thomas Krieg
Journal:  J Cell Mol Med       Date:  2020-05-08       Impact factor: 5.310

4.  Whole grain intake associated molecule 5-aminovaleric acid betaine decreases β-oxidation of fatty acids in mouse cardiomyocytes.

Authors:  Olli Kärkkäinen; Tomi Tuomainen; Ville Koistinen; Marjo Tuomainen; Jukka Leppänen; Tuomo Laitinen; Marko Lehtonen; Jaana Rysä; Seppo Auriola; Antti Poso; Pasi Tavi; Kati Hanhineva
Journal:  Sci Rep       Date:  2018-08-29       Impact factor: 4.379

5.  Protective Effects of Meldonium in Experimental Models of Cardiovascular Complications with a Potential Application in COVID-19.

Authors:  Reinis Vilskersts; Dana Kigitovica; Stanislava Korzh; Melita Videja; Karlis Vilks; Helena Cirule; Andris Skride; Marina Makrecka-Kuka; Edgars Liepinsh; Maija Dambrova
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

Review 6.  Mitochondrial Metabolism in Myocardial Remodeling and Mechanical Unloading: Implications for Ischemic Heart Disease.

Authors:  Min Jiang; Xiaoye Xie; Feng Cao; Yabin Wang
Journal:  Front Cardiovasc Med       Date:  2021-12-09

7.  Inhibition of Fatty Acid Metabolism Increases EPA and DHA Levels and Protects against Myocardial Ischaemia-Reperfusion Injury in Zucker Rats.

Authors:  Janis Kuka; Marina Makrecka-Kuka; Karlis Vilks; Stanislava Korzh; Helena Cirule; Eduards Sevostjanovs; Solveiga Grinberga; Maija Dambrova; Edgars Liepinsh
Journal:  Oxid Med Cell Longev       Date:  2021-07-28       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.